Skip to main navigation
Skip to search
Skip to main content
Utrecht University Home
Help & FAQ
Home
People
Research units
Research output
Activities
In the media
Prizes & Grants
Search by expertise, name or affiliation
BCL-2 targeting combination therapies for neuroblastoma
Lindy Vernooij
Pharmaceutics
Research output
:
Thesis
›
Doctoral thesis 2 (Research NOT UU / Graduation UU)
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'BCL-2 targeting combination therapies for neuroblastoma'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Combination Therapy
100%
Neuroblastoma
100%
B-cell Lymphoma 2 (Bcl-2)
100%
Venetoclax
100%
Targeted Combination Therapy
60%
Cancer Cells
40%
High-risk Neuroblastoma
40%
Chemotherapy
20%
Clinical Development
20%
Induced Resistance
20%
Tumor
20%
Therapeutic Strategies
20%
Treatment Strategy
20%
Therapeutic Approaches
20%
Provided Support
20%
Survival Rate
20%
Current Treatment
20%
Personalized Therapy
20%
Resistant Cells
20%
Treatment Outcome
20%
Therapy Resistance
20%
Healthy Cells
20%
Poor Prognosis
20%
Molecular Characteristics
20%
Pediatric Cancer
20%
Tumor Regression
20%
Trametinib
20%
ALK Inhibitor
20%
Precision Medicine
20%
RAS-MAPK Pathway
20%
Work Strategies
20%
Lorlatinib
20%
MDM2 Inhibitor
20%
Idasanutlin
20%
Bcl-2 Inhibitor
20%
Relapsed Patients
20%
MEK Inhibitor (MEKi)
20%
Venetoclax Resistance
20%
Mcl-1 Inhibitor
20%
Medicine and Dentistry
Combination Therapy
100%
Ganglioneuroblastoma
100%
Venetoclax
100%
Side Effect
33%
Neoplasm
16%
Induced Resistance
16%
Cancer Cell
16%
Therapy Resistance
16%
Survival Rate
16%
MEK Inhibitor
16%
Personalized Medicine
16%
Tumor Regression
16%
Patient with Neuroblastoma
16%
Idasanutlin
16%
Pediatric Cancer
16%
ALK Inhibitor
16%
Mitogen-Activated Protein Kinase
16%
Trametinib
16%
Lorlatinib
16%
Pharmacology, Toxicology and Pharmaceutical Science
Neuroblastoma
100%
Combination Therapy
100%
Venetoclax
100%
Side Effect
33%
Chemotherapy
16%
Preclinical Study
16%
Trametinib
16%
Anaplastic Lymphoma Kinase Inhibitor
16%
Lorlatinib
16%
Malignant Neoplasm
16%
Mitogen Activated Protein Kinase Kinase Inhibitor
16%
Survival Rate
16%
Therapy Resistance
16%
Tumor Regression
16%
Idasanutlin
16%
Neoplasm
16%